Clinical trials: Membranous Glomerulonephritis
Vascular Access Complication, Apheresis Related Complication
Vascular Access Complications for Therapeutic Apheresis in Nephrology
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
- Trial name
- VACTANE (NCT05894317)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
MEMBRANOUS NEPHROPATHY
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
In this study, investigators will evaluated the long-term efficacy and safety (two years) of Tacrolimus-Rituximab (RTX) therapy compared to Methylprednisolone-Cyclophosphamide (CYC) therapy in patients with primary Membranous…
- Trial name
- STARMEN (NCT01955187)
- Testing
- TACROLIMUS, RITUXIMAB, METHYLPREDNISOLONE
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Hospital Universitario 12 de Octubre
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Membranous Nephropathy, Lupus Nephritis (LN)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.
- Trial name
- NCT07038382
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Lupus Nephritis
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed.
- Trial name
- NCT00908986
- Testing
- Rituximab
- Sponsor
- Northwell Health
Hyperspectral Imaging, Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined…
- Conditions
- Hyperspectral Imaging, Idiopathic Membranous Nephropathy, Cyclophosphamide
- Trial name
- NCT05850845
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 40 people
- Sponsor
- Qianfoshan Hospital
Glomerulonephritis, Membranous, Diabetic Nephropathies
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
- Conditions
- Glomerulonephritis, Membranous, Diabetic Nephropathies, Thrombelastography, Thromboembolism
- Trial name
- NCT05656963
- Testing
- Grouping based on previous laboratory results, no intervention.
- Where
- China
- Volunteers
- 741 people
- Sponsor
- Yipeng Liu
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Nephrotic Syndrome, Membranous Nephropathy
Circulating Factors in Nephrotic Syndrome
A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis
- Trial name
- NCT06315504
- Testing
- Observation
- Volunteers
- 104 people
- Sponsor
- Iain Bressendorff
Membranous Nephropathy
Rituximab in Membranous Nephropathy
Membranous glomerulopathy (MN) is a common immune-mediated glomerular disease and the leading cause of nephrotic syndrome in Caucasian adults.
- Trial name
- NCT00425217
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Primary Membranous Nephropathy
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
- Trial name
- NCT06470191
- Testing
- B007, Cyclosporin Capsules
- Where
- 21 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Glomerulonephritis, Membranous, Glomerulosclerosis, Focal
Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental…
- Trial name
- NCT00404833
- Testing
- prednisolone and mycophenolate mofetil, prednisolone and chlorambucil
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Hospital Authority, Hong Kong
Primary Membranous Nephropathy
Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study
The goal of this observational study is to optimize the evaluation formula for the timing of initiating immunosuppressive therapy in primary membranous nephropathy in patients with primary membranous nephropathy.
- Trial name
- NCT06924476
- Where
- China
- Volunteers
- 282 people
- Sponsor
- Yipeng Liu
Membranous Nephropathy
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).
- Trial name
- NCT05810961
- Testing
- efgartigimod IV
- Where
- 31 sites in China
- Volunteers
- 8 people
- Sponsor
- argenx
Primary Membranous Nephropathy, Minimal Change Disease
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease.
- Conditions
- Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT07861113
- Testing
- Sibeprenlimab
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary Membranous Nephropathy
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
- Trial name
- MAJESTY (NCT04629248)
- Testing
- Obinutuzumab, Tacrolimus, Methylprednisolone
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
SLE, Lupus Nephritis
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse proliferative and membranous lupus nephritis with severe…
- Conditions
- SLE, Lupus Nephritis, Renal Insufficiency, End-stage Renal Disease
- Trial name
- NCT01207297
- Testing
- Tacrolimus, cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Primary Membranous Nephropathy
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
- Trial name
- CLEAR-AbKD (NCT07571746)
- Testing
- Surovatamig
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Membranous Nephropathy - PLA2R Induced
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower…
- Trial name
- NCT05679336
- Testing
- Rituximab, Cyclophosphamide, and Corticosteroids
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.